Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors

[1]  C. Roskelley,et al.  Regulation of BRCA1 expression and its relationship to sporadic breast cancer , 2002, Breast Cancer Research.

[2]  S. Noda,et al.  Characterization of AOC2 gene encoding a copper-binding amine oxidase expressed specifically in retina. , 2003, Gene.

[3]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[4]  J. Barrett,et al.  Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. , 1992, Cancer research.

[5]  Yusuke Nakamura,et al.  Methylation at CpG islands in intron 1 of EGR2 confers enhancer‐like activity , 2003, FEBS letters.

[6]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[7]  B. Karlan,et al.  Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas , 1999, Nature Genetics.

[8]  B. Oh,et al.  Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG , 2006, Nature Cell Biology.

[9]  L. Chow,et al.  The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. , 2005, Cancer research.

[10]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[11]  James E. Goldman,et al.  Protection against Fatal Sindbis Virus Encephalitis by Beclin, a Novel Bcl-2-Interacting Protein , 1998, Journal of Virology.

[12]  W. Lowry,et al.  Allele loss from chromosome 17 in ovarian cancer. , 1990, Oncogene.

[13]  Michael D. Schneider,et al.  Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy , 2005, Cell.

[14]  T. Ushijima,et al.  Detection and interpretation of altered methylation patterns in cancer cells , 2005, Nature Reviews Cancer.

[15]  H. Hibshoosh,et al.  Induction of autophagy and inhibition of tumorigenesis by beclin 1 , 1999, Nature.

[16]  S. Weitzman,et al.  Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer , 2004, Cancer Research.

[17]  Arnold J. Levine,et al.  Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Thompson,et al.  Defective autophagy leads to cancer. , 2003, Cancer cell.

[19]  A. Dobrovic,et al.  Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.

[20]  C. Caldas,et al.  Cancer genetics of epigenetic genes. , 2007, Human molecular genetics.

[21]  D. Pessayre,et al.  Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells. , 2006, World journal of gastroenterology.

[22]  O. Olopade,et al.  BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. , 2005, Cancer research.

[23]  M. King,et al.  Insights into the functions of BRCA1 and BRCA2. , 2000, Trends in genetics : TIG.

[24]  B. Levine,et al.  Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. , 2001, Cancer research.

[25]  Eva K. Lee,et al.  Predicting aberrant CpG island methylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Grignon,et al.  Loss of Heterozygosity of the BRCA 1 and Other Loci on Chromosome 17 q in Human Prostate Cancer , 2006 .

[27]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[28]  Y. Nakamura,et al.  Allelotype of human ovarian cancer. , 1991, Cancer research.

[29]  T. Henkel,et al.  Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis* , 2006, Molecular & Cellular Proteomics.

[30]  N. Tsuji,et al.  Beclin 1 augmented cis-diamminedichloroplatinum induced apoptosis via enhancing caspase-9 activity. , 2005, Experimental cell research.

[31]  D L Pincus,et al.  Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. , 1999, Genomics.

[32]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[33]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[34]  J. Rice,et al.  Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells , 1998, Oncogene.

[35]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[36]  D. Grignon,et al.  Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. , 1995, Cancer research.

[37]  S. Emr,et al.  Autophagy as a regulated pathway of cellular degradation. , 2000, Science.

[38]  D. Eccles,et al.  Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. , 1992, Oncogene.

[39]  R. Lifton,et al.  Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na–Cl cotransporter is inhibited by wild-type but not mutant WNK4 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Michael Q. Zhang,et al.  Use of Chromatin Immunoprecipitation To Clone Novel E2F Target Promoters , 2001, Molecular and Cellular Biology.

[42]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[45]  P. Chappuis,et al.  TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. , 2001, Cancer research.

[46]  H. J. Evans,et al.  p53 mutations in breast cancer. , 1992, Cancer research.

[47]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.